Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology

Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) has issued proceedings against OMass Therapeutics alleging infringement of its patents EP 3 408 286 B1 and GB 2 558 968 B relating to its proprietary miniG technology. miniG is an integral part of Nxera's NxWave™ GPCR-focused structure-based drug discovery platform.